江湖电竞赛程手机版
NEXI
US
$
0.01
0.99%
After Hours
$
1.0200
After Hours Volume:
56.06K
| Close | Chg | Chg % |
|---|---|---|
| $1.0100 | -0.1100 | -9.82% |
Volume: 1.65M
65 Day Avg: 1.6M
0.9641
Day Range
1.1100
0.9641
52 Week Range
18.7800
Overview
NEXI Overview
Key Data
- Open $1.0900
- Day Range 0.9641 - 1.1100
- 52 Week Range 0.9641 - 18.7800
- Market Cap $27.05M
- Shares Outstanding 24.16M
- Public Float 15.03M
- Beta 1.53
- Rev. per Employee N/A
- P/E Ratio N/A
- EPS -$2.6763
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 475.84K 08/15/22
- % of Float Shorted 3.17%
- Average Volume 1.6M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings
4
Full Ratings
Peering Into NexImmune's Recent Short Interest
on Benzinga.com
Why NexImmune Shares Are Rising
on Benzinga.com
NexImmune (NASDAQ: NEXI) Shoots Up After Service Agreement With Selexis
The stock of NexImmune (NASDAQ: NEXI) shot up by around 7.5% in early morning trading on Thursday following news of its service agreement with Selexis, a life sciences company. NexImmune is a clinical-stage biotechnology c...
on TipRanks.com
NexImmune (NEXI) Gets a Buy from Raymond James
In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on NexImmune (NEXI - Research Report), with a price target of $3.00. The company's shares closed yesterday at $1.26.According to TipRa...
on TipRanks.com
NexImmune (NEXI) Receives a Buy from Barclays
Barclays analyst Peter Lawson maintained a Buy rating on NexImmune (NEXI - Research Report) today and set a price target of $2.00. The company's shares closed yesterday at $1.26.Lawson covers the Healthcare sector, focusin...
on TipRanks.com
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
on Benzinga.com
Stocks That Hit 52-Week Lows On Thursday
on Benzinga.com
Stocks That Hit 52-Week Lows On Monday
on Benzinga.com
Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More
'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.
on Zacks.com
12 Health Care Stocks Moving In Monday's Intraday Session
on Benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
on Benzinga.com
Crude Oil Rises By More Than 2%; Codexis Shares Plummet
on Benzinga.com
NexImmune Inc.
NexImmune, Inc. engages in the development of novel approach to immunotheraphy designed to create therapies with curative potential for patients with cancer and other life threatening immune-mediated diseases. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke in June 7, 2011 and is headquartered in Gaithersburg, MD.